-
-
A pooled analysis of four clinical trials concluded that treatment with onabotulinumtoxinA at doses of 75-260 U administered every 12 weeks for up to five treatment cycles was efficacious, safe, and well tolerated for the prophylaxis of headache in adults with chronic migraine.
-
Myoclonus-dystonia is characterized by specific neurophysiological dysfunctions that appear to be different from the ones seen in other dystonias.
-
In this small, uncontrolled trial, autologous stem cell transplantation appeared to be efficacious for the treatment of patients with refractory CIDP.
-
In this 20-year, retrospective study, the authors summarize surgical trends in three major German epilepsy centers and identified a declining prevalence of epilepsy surgery from 1998 to 2008.
-
Ischemic stroke remains a leading cause of death worldwide, and atrial fibrillation is a major risk factor, increasing the risk of ischemic stroke five-fold in those who have a confirmed diagnosis of atrial fibrillation.
-
The need for new contraception options is clear. In the United States, about half of the some 3.4 million pregnancies each year are unintended.
-
With clearance from the Food and Drug Administration in hand, the German company licensed to market the Caya contoured diaphragm is seeking distribution and marketing partners to introduce the device in the United States.
-
-
To evaluate possible drug-drug interactions with combined pills, clinicians need to understand how the estrogen and progestin in pills are absorbed, distributed, metabolized, and eliminated.